| Name | Title | Contact Details |
|---|
Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.
ProPhase Labs (NASDAQ: PRPH) is a diversified medical science and technology company. The Company`s laboratory testing subsidiary, ProPhase Diagnostics, offers SARS-CoV-2 (COVID-19) and COVID-19 viral mutation PCR tests through both saliva and nasal swab methods at its CLIA certified laboratories. Critical to Covid testing, results are typically provided in under 24 hours. ProPhase Diagnostics also provides Respiratory Pathogen Panel (RPP) Molecular tests including Influenza A and B and others. ProPhase Labs researches, develops, manufactures, distributes, markets and sells OTC consumer healthcare products and dietary supplements, including dietary supplements under the TK Supplements® brand. The Company actively pursues strategic investments and acquisition opportunities for other companies, technologies and products.
At Gynesonics our mission is to design and develop new and advanced technologies for improving women`s health. We are focused on providing an incision-free option to women and the physicians who care for them, in treating symptomatic uterine fibroids. We are initiating a pivotal IDE trial in the United States to verify the safety and efficacy of the Sonata system, in preserving the uterus while treating those fibroids associated with abnormal uterine bleeding that are difficult to treat with existing technology and surgical techniques. We are committed to providing women with a safe and effective incision-free alternative to the invasive surgical techniques of hysterectomy or myomectomy for their severe menstrual symptoms associated with fibroids.
TRG Healthcare is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PROTAC, LLC, Is a 100% veteran-owned small business that offers a variety of training and health programs for service members and athletes.